Media.Player

Inhibition Of Protein Tyrosine Phosphatase - Sigma For Hematopoietic Regeneration

Technology Benefits

15 fold increase in hematologic recoveryApplicable for both white and red blood cell regenerationExtensively characterized mechanism of action

Technology Application

Treatment of patients undergoing hematopoietic cell transplantationTreatment of myelosuppressive chemotherapyTreatment of anemia caused by chronic kidney disease in patients on dialysis

Detailed Technology Description

UCLA researchers in the Departments of Medicine and Chemistry and Biochemistry have identified a novel receptor, Protein tyrosine phosphatase sigma (PTPS) expressed on hematopoitic stem cells. They have characterized the mechanism extensively in vivo by knockout studies and found that PTPS regulates HSC regeneration. Based on their discovery, they have developed novel inhibitors targeting PTPS that cause dramatic hematopoitic stem cell regeneration in mice models and significantly improve the life span in mice receiving fatal irradiation.

Others

State Of Development

• Identification and validation of PTPS receptor by knockout studies in mice
• Inhibitors developed and tested in mice models

Background

Depletion of white and red blood cells also known as Myelosuppression is a common side effect of chemotherapy and radiotherapy. Currently, one FDA approved growth factor is used that increases white blood cell count but there are no therapies for total blood cell regeneration. Hematopoietic stem cells (HSCs) offer an alternative therapy, as they are a reservoir of both white and red blood cells. However, the mechanistic details of factors that govern HSC regeneration and proliferation are not known and no therapeutics that can increase HSC regeneration are available.

Related Materials

Quarmyne, M., Doan, P.L., Himburg, H.A., Yan, X., Nakamura, M., Zhao, L., Chao, N.J., and Chute, J.P. (2015). Protein tyrosine phosphatase-s regulates hematopoietic stem cell-repopulating capacity. J. Clin. Invest. 125, 177–182.

Additional Technologies by these Inventors

• Pegylated Pleiotrophin (PEG-PTN) Promotes Hematopoietic Stem Cell Expansion and Hematopoietic Regeneration
• Targeted Inhibition of Human Multiple Myeloma

Tech ID/UC Case

27473/2016-518-0

Related Cases

2016-518-0

*Abstract

UCLA Researchers have identified a novel pharmacological target for hematopoietic stem cell regeneration. They have developed small molecule inhibitors against the target and shown that the inhibitors cause rapid stem cell regeneration.

*Principal Investigator

Name: John Chute

Department:

Name: Michael Jung

Department:

Name: Emelyne Diers

Department:

Country/Region

USA